At Slingshot Biosciences, we’re transforming cell-based applications with the most robust, scalable, and reproducible cell mimics including TruCytes™ Biomarker controls, SpectraComp® compensation controls, ViaComp® cell health controls, and FlowCytes® instrument controls. Our TruCytes cell mimics precisely replicate real cells' optical and biochemical properties—without the quality, sourcing, or cost challenges of traditional controls. Trusted in cell-based applications across cell therapy, drug development, and diagnostics, they empower process and analytical development, quality control, potency assessments, multi-site validations, clinical research studies, and assay development and validation. Accelerate your research and elevate your cell-based assays with our shelf-stable, on-demand cell mimic solutions that deliver breakthrough reproducibility, scalability, and cost-effectiveness. Learn more at slingshotbio.com.
$15M sweet spot round size
2012
$15M
from 2 investors over 1 rounds
Slingshot Biosciences raised $15M on May 26, 2024
Investors: Anterra Capital and + 3 Other investors